Treatment of refractory bone pain with intravenous lidocaine, ketamine and magnesium sulfate in a patient with CamuratiEngelmann Disease. Case report
Tratamento de dor óssea refratária com lidocaína, cetamina e sulfato de magnésio por via venosa em paciente portadora da Doença de Camurati-Engelmann. Relato de caso
Emica Shimozono; Vanessa Henriques Carvalho
Abstract
CASE REPORT: A female patient, 38 years old, diagnosed with CED at 16 years old, with intense chronic widespread pain, functional limitation and previous unsuccessful treatments. She underwent a serial intravenous infusion of lidocaine, ketamine, and magnesium sulfate associated with opioid use, resulting in a significant reduction in pain intensity, improvement in physical limitation and increasing the interval between pain attacks. This report is unprecedented, with no previous description of this therapeutic approach to control pain in this disease.
CONCLUSION: Treatment with intravenous infusion of lidocaine, ketamine and magnesium sulfate associated with opioid can be a safe option for treating refractory pain related to CED.
Keywords
Resumo
Palavras-chave
References
1 Klemm P, Aykara I, Lange U. Camurati-Engelmann Disease: a case- based review about an ultrarare bone dysplasia. Eur J Rheumatol. 2023;10(1):34-8.
2 Fernandes GCD, Souza DL, Yamada ES, Sunahara ERM, Menin RC, Toledo RA. Doença de Camurati-Engelmann: relato de caso. Rev Med. 2009;88(3-4):181-5.
3 Bogas M, Bogas V, Pinto F. Camurati-Engelmann disease: typical manifestations of a rare disease. Br J Rheumatol. 2009;49(3):308-14. http://doi.org/10.1590/S0482-50042009000300012.
4 Gálvez LA, Gafaro MPG, Soto KE, Álvarez CB. Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report. Rev Soc Esp Dolor. 2022;29(1):51-5. http://dx.doi.org/10.20986/resed.2021.3930/2021.
5 Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, Guañabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melançon S, Cundy T, Van Hul W. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2005;43(1):1-11.
6 Lauretti GR. Mecanismos envolvidos na analgesia da lidocaína por via venosa. Rev Bras Anestesiol. 2008;58(3):280-6.
7 Estebe JP. Intravenous lidocaine. Best Pract Res Clin Anaesthesiol. 2017;31(4):513-21.
8 Souza MF, Kraychete DC. The analgesic effect of intravenous lidocaine in treatment of chronic pain: a literature review. Rev Bras Reumatol. 2014;54(5):386-92. PMid:25627303.
9 Hutchins D, Rockett M. The use of atypical analgesics by intravenous infusion for acute pain: evidence base for lidocaine, ketamine and magnesium. Anaesth Intensive Care Med. 2019;20(8):415-8.
10 Striebel J, Ruppen W, Schneider T. Simultaneous application of lidocaine and ketamine during ambulatory infusion therapy: a retrospective analysis. Pain Manag. 2023;13(9):539-53.
11 Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 2020;13(2):135-46.
12 Nakamura A, Hasebe D, Kato Y, Nishiyama H, Hayashi T, Kobayashi T. Intravenous administration of lidocaine and magnesium for severe pain caused by primary chronic osteomyelitis of the mandible: a case report. Oral and Maxillofacial Surg Cases. 2022;8(2):100251.
13 Shin HJ, Na HS, Do SH. Magnesium and pain. Nutrients. 2020;12(8):2184.
Submitted date:
05/01/2024
Accepted date:
03/29/2025